J Kellogg Parsons1, David Zahrieh2, James L Mohler3, Electra Paskett4, Donna E Hansel5, Adam S Kibel6, Heshan Liu2, Drew K Seisler2, Loki Natarajan7, Martha White7, Olwen Hahn8, John Taylor8, Sheri J Hartman9, Sean P Stroup10, Peter Van Veldhuizen11, Lannis Hall12, Eric J Small13, Michael J Morris14, John P Pierce9, James Marshall15. 1. Department of Urology, UC San Diego Moores Comprehensive Cancer Center and VA San Diego Healthcare System, La Jolla, California. 2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota. 3. Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York. 4. Comprehensive Cancer Center, Department of Medicine, The Ohio State University College of Medicine, Columbus. 5. Department of Pathology, University of California, San Diego, La Jolla. 6. Division of Urology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts. 7. Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health and UC San Diego Moores Comprehensive Cancer Center, La Jolla, California. 8. Alliance Central Protocol Operations, University of Chicago, Chicago, Illinois. 9. Moores Cancer Center, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla. 10. Department of Urology, Naval Medical Center San Diego, San Diego, California. 11. Menorah Medical Center, Midwest Oncology Associates, Overland Park, Kansas. 12. Siteman Cancer Center, Department of Radiation Oncology, Washington University, St Peters, Missouri. 13. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. 14. Memorial Sloan Kettering Cancer Center, New York, New York. 15. Department of Prevention and Population Sciences, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Abstract
Importance: Guidelines endorsing vegetable-enriched diets to improve outcomes for prostate cancer survivors are based on expert opinion, preclinical studies, and observational data. Objective: To determine the effect of a behavioral intervention that increased vegetable intake on cancer progression in men with early-stage prostate cancer. Design, Setting, and Participants: The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]) was a randomized clinical trial conducted at 91 US urology and medical oncology clinics that enrolled 478 men aged 50 to 80 years with biopsy-proven prostate adenocarcinoma (International Society of Urological Pathology grade group = 1 in those <70 years and ≤2 in those ≥70 years), stage cT2a or less, and serum prostate-specific antigen (PSA) level less than 10 ng/mL. Enrollment occurred from January 2011 to August 2015; 24-month follow-up occurred from January 2013 to August 2017. Interventions: Patients were randomized to a counseling behavioral intervention by telephone promoting consumption of 7 or more daily vegetable servings (MEAL intervention; n = 237) or a control group, which received written information about diet and prostate cancer (n = 241). Main Outcomes and Measures: The primary outcome was time to progression; progression was defined as PSA level of 10 ng/mL or greater, PSA doubling time of less than 3 years, or upgrading (defined as increase in tumor volume or grade) on follow-up prostate biopsy. Results: Among 478 patients randomized (mean [SD] age, 64 [7] years; mean [SD] PSA level, 4.9 [2.1] ng/mL), 443 eligible patients (93%) were included in the primary analysis. There were 245 progression events (intervention: 124; control: 121). There were no significant differences in time to progression (unadjusted hazards ratio, 0.96 [95% CI, 0.75 to 1.24]; adjusted hazard ratio, 0.97 [95% CI, 0.76 to 1.25]). The 24-month Kaplan-Meier progression-free percentages were 43.5% [95% CI, 36.5% to 50.6%] and 41.4% [95% CI, 34.3% to 48.7%] for the intervention and control groups, respectively (difference, 2.1% [95% CI, -8.1% to 12.2%]). Conclusions and Relevance: Among men with early-stage prostate cancer managed with active surveillance, a behavioral intervention that increased vegetable consumption did not significantly reduce the risk of prostate cancer progression. The findings do not support use of this intervention to decrease prostate cancer progression in this population, although the study may have been underpowered to identify a clinically important difference. Trial Registration: ClinicalTrials.gov Identifier: NCT01238172.
RCT Entities:
Importance: Guidelines endorsing vegetable-enriched diets to improve outcomes for prostate cancer survivors are based on expert opinion, preclinical studies, and observational data. Objective: To determine the effect of a behavioral intervention that increased vegetable intake on cancer progression in men with early-stage prostate cancer. Design, Setting, and Participants: The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]) was a randomized clinical trial conducted at 91 US urology and medical oncology clinics that enrolled 478 men aged 50 to 80 years with biopsy-proven prostate adenocarcinoma (International Society of Urological Pathology grade group = 1 in those <70 years and ≤2 in those ≥70 years), stage cT2a or less, and serum prostate-specific antigen (PSA) level less than 10 ng/mL. Enrollment occurred from January 2011 to August 2015; 24-month follow-up occurred from January 2013 to August 2017. Interventions: Patients were randomized to a counseling behavioral intervention by telephone promoting consumption of 7 or more daily vegetable servings (MEAL intervention; n = 237) or a control group, which received written information about diet and prostate cancer (n = 241). Main Outcomes and Measures: The primary outcome was time to progression; progression was defined as PSA level of 10 ng/mL or greater, PSA doubling time of less than 3 years, or upgrading (defined as increase in tumor volume or grade) on follow-up prostate biopsy. Results: Among 478 patients randomized (mean [SD] age, 64 [7] years; mean [SD] PSA level, 4.9 [2.1] ng/mL), 443 eligible patients (93%) were included in the primary analysis. There were 245 progression events (intervention: 124; control: 121). There were no significant differences in time to progression (unadjusted hazards ratio, 0.96 [95% CI, 0.75 to 1.24]; adjusted hazard ratio, 0.97 [95% CI, 0.76 to 1.25]). The 24-month Kaplan-Meier progression-free percentages were 43.5% [95% CI, 36.5% to 50.6%] and 41.4% [95% CI, 34.3% to 48.7%] for the intervention and control groups, respectively (difference, 2.1% [95% CI, -8.1% to 12.2%]). Conclusions and Relevance: Among men with early-stage prostate cancer managed with active surveillance, a behavioral intervention that increased vegetable consumption did not significantly reduce the risk of prostate cancer progression. The findings do not support use of this intervention to decrease prostate cancer progression in this population, although the study may have been underpowered to identify a clinically important difference. Trial Registration: ClinicalTrials.gov Identifier: NCT01238172.
Authors: Matthew J Resnick; Christina Lacchetti; Jonathan Bergman; Ralph J Hauke; Karen E Hoffman; Terrence M Kungel; Alicia K Morgans; David F Penson Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: JoAnn E Manson; Nancy R Cook; I-Min Lee; William Christen; Shari S Bassuk; Samia Mora; Heike Gibson; Christine M Albert; David Gordon; Trisha Copeland; Denise D'Agostino; Georgina Friedenberg; Claire Ridge; Vadim Bubes; Edward L Giovannucci; Walter C Willett; Julie E Buring Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Meelan Bul; Xiaoye Zhu; Riccardo Valdagni; Tom Pickles; Yoshiyuki Kakehi; Antti Rannikko; Anders Bjartell; Deric K van der Schoot; Erik B Cornel; Giario N Conti; Egbert R Boevé; Frédéric Staerman; Jenneke J Vis-Maters; Henk Vergunst; Joris J Jaspars; Petra Strölin; Erik van Muilekom; Fritz H Schröder; Chris H Bangma; Monique J Roobol Journal: Eur Urol Date: 2012-11-12 Impact factor: 20.096
Authors: Joanne Frattaroli; Gerdi Weidner; Ann M Dnistrian; Colleen Kemp; Jennifer J Daubenmier; Ruth O Marlin; Lila Crutchfield; Loren Yglecias; Peter R Carroll; Dean Ornish Journal: Urology Date: 2008-07-07 Impact factor: 2.649
Authors: Stacey A Kenfield; Nicolas H Hart; Robert U Newton; June M Chan; Kerry S Courneya; James Catto; Stephen P Finn; Rosemary Greenwood; Daniel C Hughes; Lorelei Mucci; Stephen R Plymate; Stephan F E Praet; Emer M Guinan; Erin L Van Blarigan; Orla Casey; Mark Buzza; Sam Gledhill; Li Zhang; Daniel A Galvão; Charles J Ryan; Fred Saad Journal: BMJ Open Date: 2018-05-14 Impact factor: 2.692
Authors: Natasha Gupta; Hiten D Patel; Jacob Taylor; James F Borin; Kenneth Jacobsohn; Stacey A Kenfield; Scott E Eggener; Carrie Price; Meena Davuluri; Nataliya Byrne; Trinity J Bivalacqua; Stacy Loeb Journal: Prostate Cancer Prostatic Dis Date: 2022-07-05 Impact factor: 5.455
Authors: Tyler J Nelson; Juan Javier-DesLoges; Rishi Deka; P Travis Courtney; Vinit Nalawade; Loren Mell; James Murphy; J Kellogg Parsons; Brent S Rose Journal: JAMA Netw Open Date: 2021-05-03
Authors: Daniel R Schmidt; Rutulkumar Patel; David G Kirsch; Caroline A Lewis; Matthew G Vander Heiden; Jason W Locasale Journal: CA Cancer J Clin Date: 2021-05-13 Impact factor: 286.130
Authors: Maria G Grammatikopoulou; Konstantinos Gkiouras; Stefanos Τ Papageorgiou; Ioannis Myrogiannis; Ioannis Mykoniatis; Theodora Papamitsou; Dimitrios P Bogdanos; Dimitrios G Goulis Journal: Nutrients Date: 2020-09-29 Impact factor: 5.717
Authors: Christopher J D Wallis; James W F Catto; Antonio Finelli; Adam W Glaser; John L Gore; Stacy Loeb; Todd M Morgan; Alicia K Morgans; Nicolas Mottet; Richard Neal; Tim O'Brien; Anobel Y Odisho; Thomas Powles; Ted A Skolarus; Angela B Smith; Bernadett Szabados; Zachary Klaassen; Daniel E Spratt Journal: Eur Urol Date: 2020-09-04 Impact factor: 20.096
Authors: Crystal S Langlais; Rebecca E Graff; Erin L Van Blarigan; Nynikka R Palmer; Samuel L Washington; June M Chan; Stacey A Kenfield Journal: Curr Oncol Rep Date: 2021-03-10 Impact factor: 5.075